EBOS Group Ltd
ASX:EBO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.6), the stock would be worth AU$26.54 (52% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.4 | AU$17.45 |
0%
|
| 3-Year Average | 0.6 | AU$26.54 |
+52%
|
| 5-Year Average | 0.6 | AU$27.83 |
+60%
|
| Industry Average | 7.8 | AU$348.37 |
+1 896%
|
| Country Average | 3.2 | AU$140.8 |
+707%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
AU$6.6B
|
/ |
Jan 2026
AU$13B
|
= |
|
|
AU$6.6B
|
/ |
Jun 2026
AU$13.7B
|
= |
|
|
AU$6.6B
|
/ |
Jun 2027
AU$14.4B
|
= |
|
|
AU$6.6B
|
/ |
Jun 2028
AU$15.1B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| NZ |
|
EBOS Group Ltd
ASX:EBO
|
4.4B AUD | 0.4 | 15.5 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 0.3 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 0.2 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 0.2 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 0.2 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 2.9 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 0.3 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 0.9 | 22.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 1.3 | 16.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.8 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61B HKD | 0 | 7.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 1.7 |
| Median | 3.2 |
| 70th Percentile | 5.7 |
| Max | 23.9 |
Other Multiples
EBOS Group Ltd
Glance View
In the sprawling landscape of the Australasian healthcare and animal care markets, EBOS Group Ltd. stands as a towering presence, orchestrating a symphony of operations that span distribution, logistics, and retail. Established decades ago, EBOS has meticulously expanded its footprint to become a vital linchpin in the supply chain of healthcare and animal care products. Understanding its core operations is akin to peering into a well-oiled machine where efficiency reigns supreme. At the heart of EBOS's business model is its distribution segment, which acts as a conduit for pharmaceutical and healthcare products from manufacturers to a diverse range of clients including hospitals, pharmacies, and aged care facilities. This seamless distribution network is supported by state-of-the-art logistics capabilities, enabling the company to ensure timely and reliable delivery of crucial healthcare supplies across the region. Beyond distribution, EBOS has judiciously diversified into animal care and retail, recognizing the intertwining of human and animal welfare in contemporary lifestyles. Its procurement and distribution of veterinary products capitalize on the robust and growing pet care market, which has seen a surge in demand as households increasingly consider pets as part of the family. The company's retail arm, featuring well-known banners like TerryWhite Chemmart, brings it closer to consumers, providing a direct link to end-users and fortifying its revenue streams. By embracing these complementary business segments, EBOS not only ensures a balanced portfolio but also leverages synergies to maximize profit margins. Thus, through a blend of comprehensive distribution networks and strategic retail positions, EBOS Group Ltd. adeptly maneuvers within its markets, translating efficiency and scale into consistent, sustainable growth.